Evidence on Nirsevimab- and Clesrovimab immunization to prevent RSV- associated respiratory tract infections in preterm born children younger than 24 months: a scoping review protocol | Synapse
February 2, 20260 citationsOpen Access
Evidence on Nirsevimab- and Clesrovimab immunization to prevent RSV- associated respiratory tract infections in preterm born children younger than 24 months: a scoping review protocol
To evaluate the effectiveness of nirsevimab and clesrovimab immunization in preventing RSV-related respiratory infections in preterm children under 24 months.
Conduct a scoping review to gather existing literature
Focus on preterm children younger than 24 months
Analyze data regarding nirsevimab and clesrovimab interventions
Expected to identify gaps in current immunization strategies
Aim to summarize intervention effects on RSV infections
Potentially highlight the need for further research in this area